3-氨基-1-甲基-1H-吡唑盐酸盐 | 127107-29-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 亚胺内酰胺
• 中文名称: 3-氨基-1-甲基-1H-吡唑盐酸盐
• 英文名称: 3-amino-1-methylpyrazole hydrochloride
• 英文别名: 1-methylpyrazol-3-amine;hydrochloride
• CAS: 127107-29-3
• 化学式: C₄H₇N₃*ClH
• 分子量: 133.581
• InChiKey: TUDAAXXXYJNTBQ-UHFFFAOYSA-N

物化性质

• 熔点：
  203-208°C (decomposition)

计算性质

• 辛醇/水分配系数(LogP)：
  0.42
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  43.8
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  3-氨基-1-甲基-1H-吡唑盐酸盐 在 盐酸 、 sodium nitrite 、 copper(II) chloride dihydrate 、 二氧化硫 、 溶剂黄146 、 copper(l) chloride 作用下， 以 水 、 乙腈 为溶剂， 反应 0.75h， 以38%的产率得到1-甲基吡唑-3-磺酰氯
  参考文献：
  名称：

  [EN] SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME
  [FR] SULFONYLURÉES, COMPOSÉS APPARENTÉS, ET LEUR UTILISATION

  摘要：

  公开号：

  WO2016131098A8
• 作为产物：
  描述：

  N-甲基-3-氨基吡唑 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 3-氨基-1-甲基-1H-吡唑盐酸盐
  参考文献：
  名称：

  Garrone, Adele; Fruttero, Roberta; Tironi, Carla, Journal of the Chemical Society. Perkin transactions II, 1989, p. 1941 - 1946

  摘要：

  DOI：

文献信息

• PYRAZINAMIDE COMPOUND
  申请人：Umemiya Hiroki

  公开号：US20100190980A1

  公开（公告）日：2010-07-29

  Disclosed is a pyrazinamide compound represented by the formula (1), a tautomer, stereoisomer or pharmaceutically acceptable salt thereof, or a solvate of the compound or the tautomer, stereoisomer or pharmaceutically acceptable salt thereof, which has an excellent GK-activating activity and is therefore useful as a medicinal agent. (1) wherein R 1 represents a hydrogen atom, a C 1-8 alkyl group, a C 3-8 cycloalkyl group, a C 2-9 heterocyclyl group, a phenyl group, a C 1-9 heteroaryl group, a C 7-14 arylalkyl group or the like; R 2 represents a C 1-8 alkyl group, a C 2-9 heterocyclyl group, a phenyl group, a C 1-9 heteroaryl group or the like; Ar represents a monocyclic or fused polycyclic C 1-9 heteroaryl group represented by the formula (2) or a C 2-9 heterocyclyl group represented by formula (2); Y represents —S—, —O— or —NH—; and Z represents —S—, —O— or —CH 2 —.

  本发明公开了一种吡嗪酰胺化合物，其由式（1）表示，其中R1代表氢原子、C1-8烷基、C3-8环烷基、C2-9杂环基、苯基、C1-9杂环基、C7-14芳基烷基等；R2代表C1-8烷基、C2-9杂环基、苯基、C1-9杂环基等；Ar代表由式（2）表示的单环或融合多环的C1-9杂环基或由式（2）表示的C2-9杂环基；Y代表—S—、—O—或—NH—；Z代表—S—、—O—或—CH2—。该化合物或其互变异构体、立体异构体、药学上可接受的盐或其溶剂，具有出色的GK激活活性，因此作为药物剂使用。
• SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE
  申请人：Xi Ning

  公开号：US20150274704A1

  公开（公告）日：2015-10-01

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

  本发明提供了新型杂环芳基化合物、药物可接受的盐及其制剂，可用于预防、治疗或减轻蛋白激酶介导的疾病的严重程度。本发明还提供了包含这些化合物的药物可接受的组合物以及使用这些组合物治疗蛋白激酶介导的疾病的方法。
• Substituted heteroaryl compounds and methods of use
  申请人：Calitor Sciences, LLC

  公开号：US09403801B2

  公开（公告）日：2016-08-02

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

  本发明提供了新颖的杂环芳基化合物、药学上可接受的盐及其制剂，用于预防、治疗或减轻蛋白激酶介导的疾病的严重程度。本发明还提供了包含这些化合物的药学上可接受的组合物和使用这些组合物治疗蛋白激酶介导的疾病的方法。
• Base-free transfer hydrogenation of aryl-ketones, alkyl-ketones and alkenones catalyzed by an IrIIICp* complex bearing a triazenide ligand functionalized with pyrazole
  作者：Layla J. Medrano-Castillo、Miguel Á. Collazo-Flores、Juan P. Camarena-Díaz、Erick Correa-Ayala、Daniel Chávez、Douglas B. Grotjahn、Arnold L. Rheingold、Valentín Miranda-Soto、Miguel Parra-Hake

  DOI：10.1016/j.ica.2020.119551

  日期：2020.7

  An (IrCp)-Cp-III* complex (2) bearing a triazenide ligand functionalized with pyrazole was synthesized and fully characterized by spectroscopic methods and the structure confirmed by X-ray diffraction studies. The catalytic activity of 2 and the control complex 3, which lacks of pyrazole in its structure, was evaluated in the reduction of aryl-ketones, alkyl-ketones, alpha,beta-unsaturated and gamma, delta-unsaturated ketones. The catalytic system, using either 2 or 3, exhibited good to excellent selectivity when tested with ketones and alkenones at 90 degrees C in 2-propanol as hydrogen source under base-free conditions. Reactivity of 2 in 2-propanol and NaH gave a neutral metal hydride (4) while in the absence of base gave two major cationic hydrides species (5 and 6).
• EP2157090
  申请人：——

  公开号：——

  公开（公告）日：——